La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !
China Shineway Pharmaceutical Group Bilan de santé
Santé financière contrôle des critères 5/6
China Shineway Pharmaceutical Group possède un total de capitaux propres de CN¥7.0B et une dette totale de CN¥300.0M, ce qui porte son ratio d'endettement à 4.3%. Son actif total et son passif total sont CN¥9.6B et de CN¥2.5B. L'EBIT de China Shineway Pharmaceutical Group est CN¥970.1M ce qui fait que son ratio de couverture des intérêts -9.4. Elle dispose de liquidités et de placements à court terme de CN¥5.9B.
Informations clés
4.5%
Ratio d'endettement
CN¥330.00m
Dette
| Ratio de couverture des intérêts | -5.7x |
| Argent liquide | CN¥6.23b |
| Fonds propres | CN¥7.34b |
| Total du passif | CN¥2.55b |
| Total des actifs | CN¥9.88b |
Mises à jour récentes de la santé financière
Is China Shineway Pharmaceutical Group (HKG:2877) A Risky Investment?
May 13
China Shineway Pharmaceutical Group (HKG:2877) Seems To Use Debt Rather Sparingly
Sep 28China Shineway Pharmaceutical Group (HKG:2877) Has A Rock Solid Balance Sheet
Apr 07We Think China Shineway Pharmaceutical Group (HKG:2877) Can Manage Its Debt With Ease
Dec 10
Recent updates
If EPS Growth Is Important To You, China Shineway Pharmaceutical Group (HKG:2877) Presents An Opportunity
Jun 03Is China Shineway Pharmaceutical Group (HKG:2877) A Risky Investment?
May 13China Shineway Pharmaceutical Group (HKG:2877) Has Announced That It Will Be Increasing Its Dividend To CN¥0.461
Apr 26Are Investors Undervaluing China Shineway Pharmaceutical Group Limited (HKG:2877) By 41%?
Apr 17China Shineway Pharmaceutical Group (HKG:2877) Is Increasing Its Dividend To CN¥0.461
Mar 31China Shineway Pharmaceutical Group Limited's (HKG:2877) 26% Price Boost Is Out Of Tune With Earnings
Mar 14Does China Shineway Pharmaceutical Group (HKG:2877) Deserve A Spot On Your Watchlist?
Jan 29China Shineway Pharmaceutical Group (HKG:2877) Seems To Use Debt Rather Sparingly
Sep 28China Shineway Pharmaceutical Group (HKG:2877) Is Paying Out A Dividend Of CN¥0.118
Sep 01We Ran A Stock Scan For Earnings Growth And China Shineway Pharmaceutical Group (HKG:2877) Passed With Ease
Aug 03Are Investors Undervaluing China Shineway Pharmaceutical Group Limited (HKG:2877) By 44%?
May 30We Ran A Stock Scan For Earnings Growth And China Shineway Pharmaceutical Group (HKG:2877) Passed With Ease
Mar 07China Shineway Pharmaceutical Group's (HKG:2877) Dividend Will Be Reduced To CN¥0.125
Sep 01China Shineway Pharmaceutical Group Limited Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
Mar 31China Shineway Pharmaceutical Group (HKG:2877) Has A Rock Solid Balance Sheet
Apr 07China Shineway Pharmaceutical Group's(HKG:2877) Share Price Is Down 55% Over The Past Three Years.
Mar 11Should You Buy China Shineway Pharmaceutical Group Limited (HKG:2877) For Its Dividend?
Feb 18Should You Use China Shineway Pharmaceutical Group's (HKG:2877) Statutory Earnings To Analyse It?
Jan 31Is China Shineway Pharmaceutical Group Limited (HKG:2877) Trading At A 49% Discount?
Jan 13What Is The Ownership Structure Like For China Shineway Pharmaceutical Group Limited (HKG:2877)?
Dec 25We Think China Shineway Pharmaceutical Group (HKG:2877) Can Manage Its Debt With Ease
Dec 10Reflecting on China Shineway Pharmaceutical Group's (HKG:2877) Share Price Returns Over The Last Five Years
Nov 25Analyse de la situation financière
Passif à court terme: Les actifs à court terme de 2877 ( CN¥8.2B ) dépassent ses passifs à court terme ( CN¥2.4B ).
Passif à long terme: Les actifs à court terme de 2877 ( CN¥8.2B ) dépassent ses passifs à long terme ( CN¥105.5M ).
Historique et analyse du ratio d'endettement
Niveau d'endettement: 2877 dispose de plus de liquidités que de sa dette totale.
Réduire la dette: Le ratio d'endettement de 2877 est passé de 0% à 4.3% au cours des 5 dernières années.
Couverture de la dette: La dette de 2877 est bien couverte par le flux de trésorerie opérationnel ( 310.9% ).
Couverture des intérêts: 2877 gagne plus d'intérêts qu'il n'en paie, donc la couverture des paiements d'intérêts n'est pas un problème.